2013 Mid-Year Review of Nanotech Patent Class 977

FL
Foley & Lardner

Contributor

Foley & Lardner LLP looks beyond the law to focus on the constantly evolving demands facing our clients and their industries. With over 1,100 lawyers in 24 offices across the United States, Mexico, Europe and Asia, Foley approaches client service by first understanding our clients’ priorities, objectives and challenges. We work hard to understand our clients’ issues and forge long-term relationships with them to help achieve successful outcomes and solve their legal issues through practical business advice and cutting-edge legal insight. Our clients view us as trusted business advisors because we understand that great legal service is only valuable if it is relevant, practical and beneficial to their businesses.
For the first time, the USPTO is on pace to issue over 1,000 patents of nanotechnology class 977 in a single year.
United States Food, Drugs, Healthcare, Life Sciences
To print this article, all you need is to be registered or login on Mondaq.com.

For the first time, the USPTO is on pace to issue over 1,000 patents of nanotechnology class 977 in a single year.

From 1/1/2013 to 6/30/2013, the USPTO issued 531 patents of nanotechnology class 977. Among them, 278 patents (52.4%) have at least one assignee located in the United States, proving that the US continues to be the leader in nanotechnology innovation. The US is followed by the East-Asian bloc of Japan, Korea, Taiwan and China, which together account for 170 patents (32.0%) of nanotechnology class 977.

The total number of class 977 patents issued by the USPTO in the first half of this year translates to a projected year-over-year growth of 14.8%, compared to the 16.8% growth from 2011 to 2012. Geographically, the fastest growth is seen in the number of class 977 patents issued to assignees located in China, which is projected to have a year-over-year increase of almost 100%.

Overall, the growth of class 977 patents in 2013 has been impressive. It will be exciting to see such robust growth of nanotechnology IP translate to an explosion of commercializations in the U.S.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

2013 Mid-Year Review of Nanotech Patent Class 977

United States Food, Drugs, Healthcare, Life Sciences

Contributor

Foley & Lardner LLP looks beyond the law to focus on the constantly evolving demands facing our clients and their industries. With over 1,100 lawyers in 24 offices across the United States, Mexico, Europe and Asia, Foley approaches client service by first understanding our clients’ priorities, objectives and challenges. We work hard to understand our clients’ issues and forge long-term relationships with them to help achieve successful outcomes and solve their legal issues through practical business advice and cutting-edge legal insight. Our clients view us as trusted business advisors because we understand that great legal service is only valuable if it is relevant, practical and beneficial to their businesses.
See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More